Fig 1.
Visual representation of the decision analytic model, with the inclusion of GSTP1 c.313 A>G genotyping for patient selection, prior to treatment initiation. In the genotyping branch, patients with AG or GG for GSTP1 c.313 A>G (high risk) would receive fosaprepitant as a primary preventive measure. Patients with low risk (AA) genotype would receive fosaprepitant only in the presence of grades 3 or higher CINV, for subsequent cycles. The standard branch of the model represents the usual practice, without prior patient genotype assessment, including fosaprepitant since D1. CRT: chemoradiation.
Table 1.
Cost incorporation summary.
Table 2.
Markov Chain Monte Carlo simulations.
Table 3.
Costs per test according to number of samples.
Fig 2.
Cost reduction according to sample quantity.
Cost reduction (overall cost from standard approach versus genotyping selection) calculations taking into account the number of samples per round.
Fig 3.
Overall cost for each hypothetical branch and cost reduction comparison.
Overall cost from genotyping and standard approaches, once two (A) and six (B) samples are included for PCR.
Fig 4.
Graphical representation of overall cost per patient, considering the complete treatment, in the setting of two-sample (A) and six-sample (B) analyzes, and their respective credible intervals. The vertical dotted reference line marks the patient threshold for cost-benefit.